Slide 1: Corum Group Limited FY22 Results
Corum Group Limited FY22 Results 5 September 2022
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the assurance that the results, performance or achievements expressed or implied by Company or Corum). It should not be considered as an offer or invitation to the forward-looking statements contained in
Slide 3: FY22 Financial Highlights
FY22 Financial Highlights Financials Metric FY22 Result Vs pcp H2 vs H1 Health Services revenue $12.0m + 1% (4)% Underlying EBITDA $3.7m(1) (15)%(2) + 16% Underlying NPAT $1.1m(1) (47)%(3) + 86% Operating cashflow excl net R&D tax incentive $1.7m + 18% + 24% Cash on hand $5.8m (11)% (10)% (1) Exclud
Slide 4: FY22 Operational Highlights
FY22 Operational Highlights PharmX expansion and growth • PharmXchange platform launched – a digital sales and marketing solution for suppliers that improves efficiency in pharmacies • FY22 supplier-to-pharmacy connections growth of 15% Pharmacy software progress • Group wins in the period include G
Slide 5: PharmX - Connecting the pharmacy industry
PharmX- Connecting the pharmacy industry What is PharmX? • Trusted & reliable pharmacy electronic order & invoicing gateway since 2006 • Key component of the Australian pharmacy supply chain • Connects over 99% of Pharmacies with their Wholesalers and Direct Suppliers • Developing presence and netwo
Slide 6: Delivering our strategy for PharmX
Delivering our strategy for PharmX Increase the number of suppliers • Make it easier for suppliers to connect • Deepening our engagement with suppliers • Continue to add new suppliers, now with 65 suppliers using the platform. This is YoY growth of 10%, and growth since acquisition of PharmX of 16%.
Slide 7: Delivering our strategy for PharmX
Delivering our strategy for PharmX Improving pharmacy utilisation rates • Incentivising pharmacies to increase usage – average pharmacy has 6 supplier connections. • Retail group agreements signed with key retail pharmacy groups to drive utilisation. Agreements signed in FY22 represent approximately
Slide 8: PharmX Growth
PharmX Growth New Retail Group and Supplier Agreements are beginning to deliver an uplift in utilisation rates, and an increase in the number of supplier-to-pharmacy connections. Current active connections Lead indicator – total existing (excluding certain customer Pharmacy to supplier volume reduct
Slide 9: Delivering our strategy for PharmX
Delivering our strategy for PharmX Developing new functionality - PharmXchange • An Opportunity presents because the current PharmX business model doesn’t resonate with small suppliers and therefore doesn’t resolve all the manual processing issues at pharmacy level • In addition, the current busines
Slide 10: PharmXchange – Enabling pharmacy trade
PharmXchange – Enabling pharmacy trade 10
Slide 11: PharmXchange – Enabling pharmacy trade
PharmXchange – Enabling pharmacy trade • Launched in June 22 to provide additional services to Pharmacies & Suppliers • Highly integrated with the industry proven PharmX gateway • Opportunity to develop incremental earnings stream leveraged to platform sales Key Benefits for Pharmacies Key Benefits
Slide 12: PharmXchange – progress to date
PharmXchange – progress to date PharmXchange Progress To Date • Pilot Program announced end of June 2022 • Initial Pilot included 15 Pharmacies and 10 Suppliers • Initial Pilot Suppliers include leading global pharmacy Suppliers Haleon (previously GSK Consumer Healthcare) and Revlon • Haleon launche
Slide 13: Pharmacy software progress
Pharmacy software progress Transitioning from legacy to new • Strategy to increase market share by targeting groups through our relationships and market leading Head Office product • Build on Dispense, Point of Sale and other product opportunities through these partnerships • Transition from LOTS Di
Slide 14: Other matters - update
Other matters - update CEO search Court Case M&A Recommenced after being paused Mediation in September 2022 Now having disposed of temporarily pending a review of the eCommerce, we are a fully focused business structure With full hearing currently healthtech business looking to scheduled for October
Slide 15: Financials
Financials
Slide 16: FY22 Financial Snapshot
FY22 Financial Snapshot Revenue growth continues, EBITDA remains positive Results1 H1 FY22 H2 FY22 FY22 FY21 ∆ PCP ∆ H1'22 Revenue $6,101 $5,850 $11,951 $11,875 1% -4% Underlying Expenses ($4,404) ($3,877) ($8,281) ($7,539) 10% -12% EBITDA (reported) $1,385 $1,159 $2,544 $2,995 -15% -16% EBITDA (und
Slide 17: Underlying EBITDA and NPAT Bridge
Underlying EBITDA and NPAT Bridge Revenue growth continues, investment into people and increased amortisation drives decline in profit 1Refer to Page 23 in the appendix for detailed financial statements. Excludes eCommerce segment now held as a discontinued operation. Adjusted to exclude one-off cos
Slide 18: Continued Positive Cashflow
Continued Positive Cashflow Net cash from / (Used in) Operating Activities (#039;000)1 • Operating cashflow of +$1,726k excluding R&D benefit, and +$3,281 $903 $956 including net R&D tax incentive $770 received. $559 $191 • Receipts from customers have grown 3% YoY driven by the contribution from Pharm
Slide 19: FY22 Summary
FY22 Summary Revenue growth & generating PharmX Growth Healthtech Focus cash Revenue growth of 1%, below our PharmXchange launched Now having disposed of aim of 15% growth. eCommerce, we are a fully focused Strategy in place to super charge healthtech business looking to Healthy EBITDA margin of 31%
Slide 20: Questions
Questions
Slide 21: Appendix
Appendix
Slide 22: Corporate Overview
Corporate Overview Corum Group Limited (ASX:COO) at 26 Aug 22 Capital Structure Share Price 4.0cps Shares on Issue (m) 596.8 Market Capitalisation $23.87m Options / Perf Rights (m) 2.5 Enterprise Value (Cash 30/06/22) $18.11m Diluted Issued Capital (m) 599.3 Share Price Performance 12c 8 Volume (m)
Slide 23: Profit & Loss
Profit & Loss Profit & Loss (A$000's) H1'22 H2'22 FY'22 H1'21 H2'21 FY'21 ∆ PCP ∆ H1'22 Revenue $6,101 $5,850 $11,951 $5,862 $6,013 $11,875 1% -4% Health $6,101 $5,850 $11,951 $5,862 $6,013 $11,875 0.6% -4.1% Expenses Materials and consumables ($828) ($571) ($1,399) ($867) ($732) ($1,599) -12.5% -31
Slide 24: Balance Sheet
Balance Sheet Balance Sheet (A$000's) 30 June 22 - FY22 30 June 21 - FY21 Current assets Cash and cash equivalents $5,759 $6,478 Trade and other receivables $1,085 $848 Inventories $42 $34 Income tax receivable $1,549 $1,548 Other assets $151 $298 Assets related to discontinued operations - $1,210 T
Slide 25: Cashflow
Cashflow Cash flow (A$000's) H1 FY22 #039;000 H2 FY22 #039;000 FY22 #039;000 H1 FY21 #039;000 H2 FY21 #039;000 FY21 #039;000 Cash flows from operating activities Receipts from customers $6,682 $5,900 $12,582 $5,742 $6,487 $12,229 Payments to suppliers and employees ($5,990) ($4,849) ($10,839) ($5,329) ($5,614) ($10,9
Slide 26: Share Registry
Share Registry Top holders as of 2 August 2022 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 95,746,043 16.0 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.1 3 NATIONAL NOMINEES LIMITED 38,742,512 6.5 4 MERSAULT PTY LTD <THE ENGLAND FAMILY S/F A/C> 26,766,667 4.5 5 MR DAVID GERALD M
Slide 27: Corum Group Limited
Corum Group Limited Contact: Investor.Relations@corum.com.au